Information  X 
Enter a valid email address

Avacta Group PLC Ord 10P (AVCT)

Related News

16-May-2022 02:04 PM

IN BRIEF: Avacta joint venture expands partnership with GenScript

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partne
13-Apr-2022 05:33 PM

Avacta increases shareholding in drug developer AffyXell to 22%

Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics. The London-based life biotechnology company's holding in the joint venture now stands at 22%. AffyXell was
08-Apr-2022 10:37 AM

Avacta joint venture to collaborate with Chinese biological company

Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs. The Cambridge, England-based drug developer and diagnostics company said its joint venture with Daewoong Pharmaceutical Co Ltd ca
06-Apr-2022 10:23 AM

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to £29.2 million from £18.9 million in 2020. However, revenue rises to £2.9 million from £2.1 milli
16-Mar-2022 11:38 AM

Avacta sells veterinary division to Vimian for up to £2.3 million

Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB. The Cambridge, England-based drug developer and diagnostics company said that Avacta Animal Health was acquired by Ne
28-Sep-2020 09:19 AM

Avacta deepens first-half losses on higher R&D costs

Cancer therapies and diagnostics group Avacta reported deeper first-half losses as higher research and development costs offset a rise in revenue. For the six-month period ended 30 June 2020, pre-tax losses widened to £8.1 million from £6.6
18-Oct-2019 01:08 PM

Avacta losses deepen on higher R&D spend; to raise £9m

Biotherapeutics and research reagents developer Avacta booked a deeper annual loss amid a rise in R&D spending, and said it would raise up to £9m from an equity raising. News shares in the company would bee issued at 15p each. Pre-tax losses for t
02-Oct-2018 09:39 AM

Avacta Group losses widen as R&D investment jumps 31%

Biotherapeutics and reagents producer Avacta Group said Tuesday annual losses widened following an acceleration in research and development investment. For the 12 months to 21 July, pre-tax losses widened to £10.39m from £7.89m and revenue ro
16-Apr-2018 08:29 AM

Avacta Group net losses widen as costs rise

Avacta Group, reported Monday a wider half year net loss of £4m, compared with a loss of £3.4m the previous the year, weighed by an increase in administration costs. Administration costs rose to £4.00m from £3.50m, as the firm&a
18-Jan-2018 07:31 AM

Avacta in line with market forecasts

Avacta expects revenue, operating losses and cash balances for the six months ending 31 Jan to be in line with market forecasts. The group said it was making strong progress with in-house programmes and solid progress with its partners. Group chief exec
15-Jan-2018 07:04 AM

Avacta agrees development partnership with Glythera

Avacta Group and Glythera have agreed the terms of a licensing deal which will allow them to develop drug conjugates using their combined technologies. Avacta said a successful proof-of-concept study had shown that Affimers have key technical benefits f
08-Jan-2018 09:26 AM

Avacta to host capital markets day

Avacta Group will host a capital markets day for financial analysts and institutional investors at finnCap's offices, 60 New Broad St, London, EC2M 1JJ, on 7 Feb from 2 p.m. to 4 p.m. The event will begin with a non-technical corporate update by ch
03-Jan-2018 07:38 AM

Avacta CEO to present at Biotech Showcase

Avacta Group chief executive Dr Alastair Smith will be presenting at the annual Biotech Showcase which is being held in San Francisco on 8-10 Jan. Smith will outline the key benefits of the group's Affimer technology as a therapeutic protein platf
04-Dec-2017 02:26 PM

Avacta schedules AGM

Avacta Group has confirmed that the Company intends to hold its Annual General Meeting on 18 January. At 2:26pm: (LON:AVCT) Avacta Group PLC share price was 0p at 65p Story provided by
30-Nov-2017 03:00 PM

Avacta sets up SIP, issues shares

Avacta Group said it has established an HMRC approved Share Incentive Plan for all eligible UK employees. As part of the SIP Award Scheme, shares of up to a value of £3,000 per employee will be issued at the prevailing middle market price at the c
15-Nov-2017 08:14 AM

Covance to present Affimer data at forum says Avacta

Avacta, the developer of Affimer biotherapeutics and reagents, has announced that Covance will be presenting Affimer data from a joint study at the European Bioanalysis Forum in Barcelona on 15-17 Nov. Avacta said Covance will be presenting data that h
13-Nov-2017 07:52 AM

Avacta to present at PEGS Europe

Avacta Group chief scientific officer, Dr Amrik Basran, will be presenting an update on the Affimer therapeutics programmes at the Protein and Antibody Engineering Summit which starts in Lisbon today. Basran will present recent progress in the Affimer t
24-Oct-2017 07:41 AM

Record Year for Affimers in scientific publications, says Avacta

Avacta Group, the developer of Affimer biotherapeutics and reagents, said 2017 had been a record year for scientific publications using Affimer reagents, with nine scientific papers reporting the work of leading groups world-wide. It said two recent pape
12-Oct-2017 07:47 AM

Avacta to present at Shares Spotlight Evening

Avacta Group chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 19 Oct at the Novotel Hotel, Tower Bridge, 10 Pepys Street, London, EC3N 2NR. The event, which begins at 18:00hrs, provides an opportunity for investors to
10-Oct-2017 09:55 AM

Avacta to present at the Shares Spotlight Evening in London on 19 October 2017

Looking for new investment ideas and want to meet senior directors of listed UK companies? Come along and join Shares and AJ Bell on Thursday 19 October 2017 at their evening event in London and meet Avacta (AVCT), Custodian REIT (CREI), Non-Standard Fin
10-Oct-2017 08:00 AM

Avacta CTO to present at US conference

Avacta chief technology officer, Dr Matt Johnson is presenting at the Annual Biomarkers & Precision Medicine Congress in San Diego which ends tomorrow. Johnson will be presenting new Affimer applications including data from a collaboration with Covance,
05-Oct-2017 08:56 AM

Avacta research collaboration with FIT Biotech

Avacta Group, the developer of Affimer biotherapeutics and reagents, has initiated a research collaboration with FIT Biotech Oy to assess the effectiveness of developing gene therapies using Avacta's Affimer technology combined with FIT Biotech&apos
04-Oct-2017 07:10 AM

Avacta revenues rise but losses widen

Avacta's revenues rose by 26% to £2.74m in the year to the end of July with Avacta Life Sciences revenue up at £1.15m (2016: £0.70m), in line with market expectations and Avacta Animal Health revenue of £1.59m (2016: £1.
02-Oct-2017 07:32 AM

Avacta establishes US business development team

Avacta Group has established a commercial team of three people in the US including the appointment of Dr Matthew Vincent as vice-president therapeutics business development. It said: 'In order to exploit the rapidly growing interest in Avacta'
07-Aug-2017 08:07 AM

Avacta revenues rise

Avacta Group expects revenues for the year ended 31 July to be 27% up on last time at £2.75m, in line with market forecasts. The group said the cash position was well ahead of market expectations at £13m (2016: £19.5m) and the loss be

a d v e r t i s e m e n t